JC2-11

• Description :

  JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1[1].

• UNSPSC :

  12352005

• Target :

  AIM2; NOD-like Receptor (NLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/jc2-11.html

• Purity :

  98.03

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  COC1=CC(/C=C/C(C2=CC(F)=C(C=C2)OC)=O)=CC=C1O

• Molecular Formula :

  C17H15FO4

• Molecular Weight :

  302.30

• References & Citations :

  [1]Lee G, et al, JC2-11, a benzylideneacetophenone derivative, attenuates inflammasome activation. Sci Rep. 2022 Dec 28;12 (1) :22484.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NLRP3

• CAS Number :

  [937820-89-8]